Showing posts with label international. Show all posts
Showing posts with label international. Show all posts

Wednesday, 28 August 2013

Update On Natural Alternatives International: Mannatech Is A Good Omen

As I write this, Mannatech (MTEX) is nearly a four bagger since when I first spoke about it, back in November 2012. Granted, the stock was almost for free back in November, but it's still an incredible move in little more than 9 months.

But this was supposed to be an article updating on Natural Alternatives International (NAII). So why talk about Mannatech? It happens that Mannatech is NAII's 2nd largest customer, and NAII's revenues are very concentrated:

(click to enlarge)

So Mannatech represented 17% of NAII's revenues in the last quarter. And, back then, Mannatech was shrinking so NAII's revenues from it were also shrinking. Indeed, NAII even singled out Mannatech as one of the customers having a negative impact, the other being privately held NSA International:

(click to enlarge)

This relevance forms the basis of the present update. Mannatech is not going up just because of Bernanke's actions and general stock market happiness. As we saw Mannatech - a multi-level marketer - was having trouble until recently. But due to the launch of new products and a renewed recruiting drive, Mannatech has now possibly turned the corner.

At the very least, Mannatech is no longer shrinking. It's now growing and, due to its rapid recruiting drive, it's likely to grow even faster in the near future. This much can be gathered from its latest earnings report, as follows (Source: MTEX Q2 2013 earnings report):

(click to enlarge)

Not only that, but distributor recruiting accelerated substantially, reversing the shrinking trend there as well and promising further growth in the quarters to follow:

Recruiting increased 31.2% in the second quarter 2013 as compared to the second quarter of 2012. The number of new independent associates and members for the second quarter of 2013 was approximately 36,200, as compared to 27,600 in 2012. The total number of independent associates and members based on a 12-month trailing period was approximately 240,000 as of June 30, 2013, as compared to 230,000 as of June 30, 2012.

Relevance for NAII

As we saw, Mannatech is NAII's 2nd largest customer. Up until the March quarter, MTEX was contributing negatively for NAII's revenues. Now, given the turnaround at MTEX we have some likelihood that soon it will be contributing positively for NAII.

We don't have data on NSA International, the largest customer, so this might not be enough to turn around fortunes at NAII instantly. But it helps, and reinforces the trend which I covered in my first article, regarding the FDA being stricter with dietary supplement manufacturers and that benefiting NAII.

This turnaround at MTEX thus constitutes a further positive catalyst for NAII, also aided by MTEX's significant recent stock market performance, which might bleed somewhat into NAII as investors and speculators link the two.

Conclusion

MTEX, which has had a recent blistering performance in the stock market, looks set to turn its fortunes around at least temporarily. MTEX is also NAII's second largest customer. So with MTEX seeing more sales volume, NAII might also benefit from higher revenues, whereas until recently MTEX was shrinking its orders to NAII.

This constitutes a further positive catalyst for NAII shares, to add to the previously described catalyst represented by the FDA's more strict and frequent inspections of dietary supplement manufacturers.

Disclosure: I am long NAII. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

How would you like your alerts on   delivered?

Added to your bookmarks on the Seeking Alpha homepage

new SA.Pages.Article.bookmark("_bottom");

View the original article here

Friday, 16 August 2013

International research team identifies top risk factors for children during influenza pandemic

Main Category: Pediatrics / Children's Health
Also Included In: Flu / Cold / SARS
Article Date: 15 Aug 2013 - 2:00 PDT Current ratings for:
International research team identifies top risk factors for children during influenza pandemic
not yet ratednot yet rated

An international team of pediatric specialists, representing the world's five major pediatric emergency medicine research networks, has identified several crucial risk factors for alerting clinicians to children most susceptible to life-threatening infections from the H1N1 influenza (flu). It is the first study to detail which clinical factors at hospital arrival in children with influenza-like illness and H1N1 infection are associated with the progressive risk to either severe infection or death.

In a study now on online in the prestigious British Medical Journal, researchers examined pediatric cases from dozens of emergency departments in hospitals around the world during the global influenza pandemic of 2009. The results enabled the team to pinpoint several clinical risk factors for severe infections in youngsters who arrive at a hospital with influenza-like illnesses due to H1N1 infections. The information would be invaluable during a pandemic, when emergency departments and primary-care facilities experience large surges of young patients who arrive with flu-like symptoms.

The study, which assessed each patient's clinical history and physical examination, identified the following predictors of severe H1N1 infection and potentially fatal outcomes in children:

History of chronic lung diseaseHistory of cerebral palsy/developmental delaySigns of chest retractions (difficulty breathing)Signs of dehydrationRequires oxygen to keep blood levels normalHeart rate that exceeds normal range (tachycardia) relative to age

"The basic question clinicians face when they are in the middle of an influenza epidemic like H1N1 is whether their patient is at risk of severe complications," said Stuart Dalziel, lead author of the study and a pediatrician at New Zealand's Starship Children's Hospital and The University of Auckland, and vice-chair of the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network. "One of the key strengths of this study is that it provides clinicians with meaningful and more precise information that can enable them to identify those children with fever and flu-like symptoms who are at greater risk of severe complications."

The findings stem from 265 pediatric cases culled from 79 emergency departments of hospitals associated with the Pediatric Emergency Research Networks (PERN) in 12 countries.

"Having a more accurate idea of what to look for in pediatric cases, especially during a pandemic, would be especially important to clinicians because it provides crucial guidance for those who would be trying to direct the appropriate levels of treatment for many patients in a short time," said Nathan Kuppermann, professor and chair of emergency medicine at the University of California, Davis, one of the study's senior authors and a principal investigator in the Pediatric Emergency Care Applied Research Network (PECARN).

Because of its unparalleled global network of hospitals and patient data, the PERN study also added weight to the efficacy and use of the anti-viral drug oseltamivir (trade name Tamiflu) to treat the children with H1N1 influenza virus infections to reduce the severity of infection. Researchers noted there was good evidence of an association between oseltamivir treatment and a reduced frequency of death in children admitted to an intensive care unit for assisted ventilation.

"This study shows the incredible power of PERN, bringing together five pediatric emergency research networks and many emergency departments from around the world, to produce this very significant study which has the power to identify the most at-risk children in a future influenza pandemic," said Terry P. Klassen, the study's senior author, CEO and scientific director at the Manitoba Institute of Child Health in Canada and a site investigator with Pediatric Emergency Research Canada (PERC).

The global research collaborative is comprised of the five major pediatric networks, which are located in Europe and the Middle East (Research in European Paediatric Emergency Medicine, or REPEM), North America (PECARN, PERC and the Pediatric Emergency Medicine Collaborative Research Committee), and in Australia and New Zealand (PREDICT). Together, the five networks have access to data from more than three million pediatric emergency department cases annually from more than 100 hospitals, which are located in four of the six World Health Organization (WHO) regions.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pediatrics / children's health section for the latest news on this subject.

Funding: PECARN is supported by HRSA/MCHB/EMSC through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. Stuart Dalziel is supported by the Health Research Council of New Zealand. John M.D. Thompson received funding from the Logan Campbell Trust, Auckland, New Zealand, to attend an investigator meeting, with time funded by CureKids, New Zealand. Investigators’ time was funded by their host institutions and/or research networks. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Predictors of severe H1N1 infection in children presenting within Pediatric Emergency Research Networks (PERN): retrospective case-control study

BMJ 2013; 347 doi: 10.1136/bmj.f4836

Stuart R Dalziel, John MD Thompson, Charles G Macias, Ricardo M Fernandes, David W Johnson, Yehezkel Waisman, Nicholas Cheng, Jason Acworth, James M Chamberlain, Martin H Osmond, Amy Plint, Paolo Valerio, Karen JL Black, Eleanor Fitzpatrick, Amanda S Newton, Nathan Kuppermann, Terry P Klassen

UC Davis Health System

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

UC Davis Health System. "International research team identifies top risk factors for children during influenza pandemic." Medical News Today. MediLexicon, Intl., 15 Aug. 2013. Web.
15 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'International research team identifies top risk factors for children during influenza pandemic'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Friday, 26 July 2013

Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today

Main Category: Liver Disease / Hepatitis
Also Included In: Alcohol / Addiction / Illegal Drugs
Article Date: 25 Jul 2013 - 1:00 PDT Current ratings for:
Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today
not yet ratednot yet rated

The burden of liver disease could be dramatically reduced by increasing treatment for hepatitis C infection among people who inject drugs, suggest new recommendations developed by researchers from the Kirby Institute at UNSW, in collaboration with colleagues from the International Network on Hepatitis Care in Substance Users (INHSU).

In Australia, 226,000 people are living with chronic hepatitis C and over 10,000 new cases are reported every year. Hepatitis C can lead to serious liver complications such as liver failure or cancer, which are associated with considerable costs to the health care system. Although almost 80 per cent of all infections occur among people who inject drugs, only one per cent of these people currently receive treatment.

"Treatment for hepatitis C infection among people who inject drugs remains unacceptably low," said Dr Jason Grebely, Senior Lecturer at the Kirby Institute, UNSW, and co-lead author of the recommendations. "Clinicians have been hesitant to recommend treatment in this population because of a lack of understanding about how lifestyle factors may impede successful treatment."

But research supporting the first set of international recommendations ever released for treating hepatitis C in people who inject drugs has shown that treatment can be very successful when barriers are addressed within a supportive environment.

"Reducing the significant burden of liver disease related to hepatitis C in Australia and internationally will require improved assessment and treatment of the population most affected: people who currently inject drugs and those who have injected drugs in the past," says Philip Bruggmann, President of INHSU. "By providing appropriate care to this group, we can reduce the burden of hepatitis C-related liver disease in this vulnerable population and slow the spread of this world-wide epidemic. These new recommendations serve as a first step towards elimination of hepatitis C."

The global recommendations are published online today in the journal Clinical Infectious Diseases ahead of World Hepatitis Day on July 28. They are part of a supplement entitled "Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward", developed in collaboration with INHSU.

Additional Stakeholder Comments:

"These are exceptionally positive and welcome findings. Following the listing of new hep C treatments for subsidy by the Australian Government in April, almost all people in Australia living with hepatitis C in Australia can enjoy cure rates of around 75 to 80 per cent. This new evidence shows us that people who have been least able to access treatment in the past, can and should be able to benefit from these new treatment advances."

Stuart Loveday
CEO of Hepatitis NSW

"This report is most welcomed. It finally provides the much needed endorsement that peer support requires to validate it as an efficacious treatment modality. That combined with the recognition that people who continue to inject or use drugs can access treatment will mean that more people will be able to access treatment. For too long those most affected by hepatitis C have been on the periphery, this report puts them where they belong - front and centre."

Nicky Bath
CEO of the NSW Users and AIDS Association

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our liver disease / hepatitis section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Institute, Kirby. "Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today." Medical News Today. MediLexicon, Intl., 25 Jul. 2013. Web.
26 Jul. 2013. APA
Institute, K. (2013, July 25). "Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263862.php.

Please note: If no author information is provided, the source is cited instead.


'Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today

Main Category: Liver Disease / Hepatitis
Also Included In: Alcohol / Addiction / Illegal Drugs
Article Date: 25 Jul 2013 - 1:00 PDT Current ratings for:
Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today
not yet ratednot yet rated

The burden of liver disease could be dramatically reduced by increasing treatment for hepatitis C infection among people who inject drugs, suggest new recommendations developed by researchers from the Kirby Institute at UNSW, in collaboration with colleagues from the International Network on Hepatitis Care in Substance Users (INHSU).

In Australia, 226,000 people are living with chronic hepatitis C and over 10,000 new cases are reported every year. Hepatitis C can lead to serious liver complications such as liver failure or cancer, which are associated with considerable costs to the health care system. Although almost 80 per cent of all infections occur among people who inject drugs, only one per cent of these people currently receive treatment.

"Treatment for hepatitis C infection among people who inject drugs remains unacceptably low," said Dr Jason Grebely, Senior Lecturer at the Kirby Institute, UNSW, and co-lead author of the recommendations. "Clinicians have been hesitant to recommend treatment in this population because of a lack of understanding about how lifestyle factors may impede successful treatment."

But research supporting the first set of international recommendations ever released for treating hepatitis C in people who inject drugs has shown that treatment can be very successful when barriers are addressed within a supportive environment.

"Reducing the significant burden of liver disease related to hepatitis C in Australia and internationally will require improved assessment and treatment of the population most affected: people who currently inject drugs and those who have injected drugs in the past," says Philip Bruggmann, President of INHSU. "By providing appropriate care to this group, we can reduce the burden of hepatitis C-related liver disease in this vulnerable population and slow the spread of this world-wide epidemic. These new recommendations serve as a first step towards elimination of hepatitis C."

The global recommendations are published online today in the journal Clinical Infectious Diseases ahead of World Hepatitis Day on July 28. They are part of a supplement entitled "Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward", developed in collaboration with INHSU.

Additional Stakeholder Comments:

"These are exceptionally positive and welcome findings. Following the listing of new hep C treatments for subsidy by the Australian Government in April, almost all people in Australia living with hepatitis C in Australia can enjoy cure rates of around 75 to 80 per cent. This new evidence shows us that people who have been least able to access treatment in the past, can and should be able to benefit from these new treatment advances."

Stuart Loveday
CEO of Hepatitis NSW

"This report is most welcomed. It finally provides the much needed endorsement that peer support requires to validate it as an efficacious treatment modality. That combined with the recognition that people who continue to inject or use drugs can access treatment will mean that more people will be able to access treatment. For too long those most affected by hepatitis C have been on the periphery, this report puts them where they belong - front and centre."

Nicky Bath
CEO of the NSW Users and AIDS Association

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our liver disease / hepatitis section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Institute, Kirby. "Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today." Medical News Today. MediLexicon, Intl., 25 Jul. 2013. Web.
26 Jul. 2013. APA
Institute, K. (2013, July 25). "Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263862.php.

Please note: If no author information is provided, the source is cited instead.


'Treating people who use drugs is the first step towards eliminating hepatitis C - international guidelines for treatment released today'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here